Segesterone acetate/ethinylestradiol

Segesterone acetate/ethinylestradiol
	Ethinylestradiol (top) and; segesterone acetate (bottom)
Combination of
Segesterone acetate	Progestogen
Ethinylestradiol	Estrogen
Clinical data
Trade names	Annovera
Other names	EE/SGA; EE/SA
AHFS/Drugs.com	Professional Drug Facts
MedlinePlus	a604032
License data	US DailyMed: Segesterone_acetate_and_ethinyl_estradiol;
Routes of; administration	Intravaginal
ATC code	None;
Legal status
Legal status	US: ℞-only;
Identifiers
KEGG	D11654;

Segesterone acetate/ethinylestradiol (EE/SGA), sold under the brand name Annovera, is a contraceptive vaginal ring and combined form of hormonal birth control which contains segesterone acetate, a progestin and ethinylestradiol, an estrogen.^[1]^[2]^[3] It contains 17.4 mg ethinylestradiol and 103 mg segesterone acetate, releases an average of 13 μg ethinylestradiol and 0.15 mg segesterone acetate per day.^[1]^[4]

Annovera is inserted into the vagina and left for 21 days, then removed, washed and stored for seven days, during which the user experiences a period (withdrawal bleeding.) This can be repeated thirteen times, for one full year of use.^[5] Unlike NuvaRing, another vaginal ring contraceptive, Annovera does not need to be refrigerated before being dispensed and can be stored at temperatures up to 30 degrees Celsius.^[1]

The medication was developed by the Population Council, an international non-profit organization, and licensed to TherapeuticsMD. It was approved for medical use in the United States in August 2018.^[4]^[6]

References[edit]

^ ^a ^b ^c ^d "Annovera- segesterone acetate and ethinyl estradiol ring". DailyMed. 7 August 2020. Retrieved 10 October 2020.
^ Nelson AL (October 2019). "Comprehensive overview of the recently FDA-approved contraceptive vaginal ring releasing segesterone acetate and ethinylestradiol: A new year-long, patient controlled, reversible birth control method". Expert Review of Clinical Pharmacology. 12 (10): 953–963. doi:10.1080/17512433.2019.1669448. PMID 31526281. S2CID 202674265.
^ Lee AL (May 2020). "Segesterone Acetate and Ethinyl Estradiol Vaginal Ring (Annovera) for Contraception". American Family Physician. 101 (10): 618–620. PMID 32412221.
^ ^a ^b "TherapeuticsMD Announces FDA Approval of Annovera (Segesterone Acetate/Ethinyl Estradiol Vaginal System) for Birth Control". TherapeuticsMD Inc (Press release). 10 August 2018. Retrieved 10 October 2020.
^ "FDA approves new vaginal ring for one year of birth control". U.S. Food and Drug Administration (FDS) (Press release). 10 August 2018. Retrieved 10 October 2020.
^ "Drug Approval Package: Annovera (segesterone acetate and ethinyl estradiol)". U.S. Food and Drug Administration (FDA). 10 September 2018. Retrieved 10 October 2020.

External links[edit]

"Segesterone acetate". Drug Information Portal. U.S. National Library of Medicine.
"Ethinylestradiol". Drug Information Portal. U.S. National Library of Medicine.

This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it.

[Annovera_FDA_label-1] "Annovera- segesterone acetate and ethinyl estradiol ring". DailyMed. 7 August 2020. Retrieved 10 October 2020.

[Nelson_2019-2] Nelson AL (October 2019). "Comprehensive overview of the recently FDA-approved contraceptive vaginal ring releasing segesterone acetate and ethinylestradiol: A new year-long, patient controlled, reversible birth control method". Expert Review of Clinical Pharmacology. 12 (10): 953–963. doi:10.1080/17512433.2019.1669448. PMID 31526281. S2CID 202674265.

[Lee_2020-3] Lee AL (May 2020). "Segesterone Acetate and Ethinyl Estradiol Vaginal Ring (Annovera) for Contraception". American Family Physician. 101 (10): 618–620. PMID 32412221.

[TherapeuticsMD2018-4] "TherapeuticsMD Announces FDA Approval of Annovera (Segesterone Acetate/Ethinyl Estradiol Vaginal System) for Birth Control". TherapeuticsMD Inc (Press release). 10 August 2018. Retrieved 10 October 2020.

[5] "FDA approves new vaginal ring for one year of birth control". U.S. Food and Drug Administration (FDS) (Press release). 10 August 2018. Retrieved 10 October 2020.

[6] "Drug Approval Package: Annovera (segesterone acetate and ethinyl estradiol)". U.S. Food and Drug Administration (FDA). 10 September 2018. Retrieved 10 October 2020.

[1]

[2]

[3]

[4]

[5]

[6]

See also[edit]

References[edit]

External links[edit]